An interventional study of Supervised Progressive Walking Test in Non-specific Chronic Low Back Pain, sponsored by University of Rennes 2. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by University of Rennes 2 · Not applicable, Interventional, and Basic science
Among 367 studies in Motor Activity with a site in France — 78 open to participants now, 90 under way, none of them phase 3. Motor Activity · France.
Among the 367 studies in Motor Activity with a site in France, this one is the 137th largest by planned enrollment of the 269 interventional ones, is one of 17 that started in 2026, is one of 254 with no phase, reaches primary completion later than 74 of the 89 other live ones, and was the 363rd registered.
9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 8,388 interventional studies indexed under Motor Activity.
Browse Motor Activity studies →78 of the 367 studies in Motor Activity with a site in France are open now, in 7 countries. Each count lists the studies.
Of the 1,201 Motor Activity studies recruiting now, 517 (43%) set no upper age limit and 535 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →367 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 17 started in 2026.
Median enrollment 62 across the 269 interventional studies, 98 across the 98 observational. Of the 230 that completed or were terminated, 3 (1%) have results posted.
22 of 367 have an industry lead sponsor. The 10 most frequent:
University of Rennes 2 is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
University of Rennes 2 has 5 studies filed under Motor Activity — fewer than ten, so there is no comparison to draw.
23 of the studies in Motor Activity with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05641116Centre Hospitalier Universitaire de Saint EtienneEffectiveness of an Intervention Combining Adapted Physical Activity and Therapeutic Education in Patients With Chronic Symptoms Attributed to Lyme Borreliosis. | 2026-12 |
| NCT05770089University Hospital, CaenVideoconferencing Adapted Physical Activity in Anorexia Nervosa: a Pilot Study | 2026-12-01 |
| NCT06061562University Hospital, GrenobleDown Syndrome, Physical Activity and Sleep Apnea | 2026-12-31 |
| NCT05383092University Hospital, ToulouseAdapted Physical Activity for Children Treated With Cancer and Insulin Sensitivity | 2026-12-31 |
| NCT07383844Fondation LenvalAnalysis of Barriers and Facilitators to Adapted Physical Activity for Pediatric Patients With Chronic Inflammatory Bowel Diseases | 2027-01-31 |
Among the 367 studies in Motor Activity with a site in France, from their registry updates:
This study aims to explore, in patients with chronic non-specific low back pain (cnsLBP), the relationships between lumbar muscle activity, structural and morphological characteristics of the paraspinal muscles, and movement strategies, during a functional, ecological task: walking. To do this, we will compare a group of cnsLBP patients with a group of asymptomatic subjects, combining several types of measurements taken at different walking intensities: spinal kinematics (movement strategies), electromyographic activity of the lumbar muscles, and structural parameters of the paraspinal muscles (stiffness and thickness). The objective is twofold: first, to identify any significant differences between cnsLBP patients and healthy subjects on these combined parameters; second, to explore the interactions between these three dimensions (muscle activity, muscle structure, movement strategy) in order to better understand their relationships with pain and with how CNSLBP functions during physical activity. This multidimensional, ecological approach could also help identify subgroups within the cnsLBP population, reflecting the clinical heterogeneity already documented in the literature. Ultimately, the expected results will contribute to a better understanding of the biomechanical and neuromuscular mechanisms involved during physical activity in these patients, and will provide objective elements to help individualize physical activity recommendations according to each patient's profile.
Inclusion Criteria for CNSLBP participants:
Non-inclusion criteria for CNSLBP participants :
Inclusion criteria for asymptomatic participants :
Non-inclusion criteria for asymptomatic participants :
Non-inclusion criteria common to CNSLBP and asymptomatic participants :
(*) Persons referred to in Articles L. 1121-5 to L. 1121-8 and L. 1121-12 of the French Public Health Code:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants underwent a single assessment session including lumbar muscle ultrasound imaging, functional movement task analysis and a walking test. No therapeutic intervention was administered.
Other: Supervised Progressive Walking Test
Participants underwent a single assessment session including lumbar muscle ultrasound imaging, functional movement task analysis and a walking test. No therapeutic intervention was administered.
Other: Supervised Progressive Walking Test
After a warm-up period on the treadmill, the test involves walking, starting at a speed of 3 km/h and increasing the speed by 0.5 km/h every 2 minutes, up to a maximum of 7 km/h. The speed of 7 km/h is a target speed and is not mandatory.
Change in muscle stiffness of the erector spinae and multifidus muscles between rest and after physical activity
Change in muscle stiffness, measured by shear modulus using shear-wave elastography, of the erector spinae and multifidus muscles, between rest and after physical activity.
Time frame: As the study consists of a single session, the time frame is between the pre-walking-test and post-walking-test assessments.
Ultrasound morphological measurements
Measurement of the cross-sectional area and thickness-as determined by ultrasound-of the erector spinae and multifidus muscles at rest.
Time frame: Data were collected during the experimental session.
Electromyographic activity
Lumbar muscle activations during three-dimensional lumbar movements and while walking
Time frame: Data were collected during the experimental session.
Kinematics
The kinematics of the lumbopelvic-femoral complex (segmental velocity and acceleration, joint angles) during three-dimensional movements and while walking.
Time frame: Data were collected during the experimental session.
General data
Age, sex, height, weight, body mass index, and socioeconomic status are recorded.
Time frame: Data were collected during the experimental session
Impact, effort, and sensations during the walking experience
Intensity of pain experienced, measured using a numerical rating scale at rest and during activity. Perceived exertion during walking on a treadmill, measured using the Borg CR-10 scale. Heart rate recorded using a Garmin® HRM heart rate monitor. Time, distance, and speed achieved during the walking task
Time frame: Data were collected during the experimental session
Physical function
Patients' physical function is assessed using the Oswestry Disability Index (ODI).
Time frame: Data from the questionnaire were collected during the experimental session, or shortly before (between 1 and 7 days beforehand)
Pain intensity and location
The intensity of pain experienced by participants on the day of the test, as measured by a numerical rating scale, and the location of the pain, as determined by the Pain Drawing test.
Time frame: Data were collected during the experimental session
Daily impact of pain
The daily impact of pain (daily activities, work, leisure, anxiety and depression, social life) is assessed using the Dallas Self-Report Questionnaire (DRAD).
Time frame: Data from the questionnaire were collected during the experimental session, or shortly before (between 1 and 7 days beforehand)
Quality of life health-related
Health-related quality of life is assessed using the SF-12 questionnaire (SF-12)
Time frame: Data from the questionnaire were collected during the experimental session, or shortly before (between 1 and 7 days beforehand)
Physical activity and sedentary behavior
Participants' physical activity and sedentary behavior are assessed using the French version of the Global Physical Activity Questionnaire (GPAQ).
Time frame: Data from the questionnaire were collected during the experimental session, or shortly before (between 1 and 7 days beforehand)
Kinesiophobia
Fear of physical injury related to movement is assessed using the Tampa Scale for Kinesiophobia (TSK).
Time frame: Data from the questionnaire were collected during the experimental session, or shortly before (between 1 and 7 days beforehand)
Anxiety and depressive disorders
Screening for anxiety and depressive disorders is performed using the Hospital Anxiety and Depression Scale (HAD).
Time frame: Data from the questionnaire were collected during the experimental session, or shortly before (between 1 and 7 days beforehand)
Validity of ultrasound measurements
The validity of ultrasound measurements is assessed by the intra-operator repeatability of ultrasound measurements.
Time frame: Data were collected during the experimental session
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.
Of 5,147 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 24 months is above that.
Counting every sponsor, half of 5,207 studies reached it within 17 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Rennes 2